# Study Evaluating Inotuzumab Ozogamicin In Acute Lymphocytic Leukemia

> **NCT01363297** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 72 (actual)

## Conditions studied

- Acute Lymphocytic Leukemia

## Interventions

- **DRUG:** Inotuzumab Ozogamicin

## Key facts

- **NCT ID:** NCT01363297
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-08
- **Primary completion:** 2014-08
- **Final completion:** 2016-01
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2017-04-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01363297

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01363297, "Study Evaluating Inotuzumab Ozogamicin In Acute Lymphocytic Leukemia". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01363297. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*